Dr. Daver on Results of a Combination Study With Azacitidine/Nivolumab in AML

Video

In Partnership With:

Naval G. Daver, MD, discusses the results of a phase Ib/II study that evaluated the combination of azacitidine and nivolumab (Opdivo) in patients with relapsed/refractory acute myeloid leukemia.

Naval G. Daver, MD, associate professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, discusses the results of a phase Ib/II study that evaluated the combination of azacitidine and nivolumab (Opdivo) in patients with relapsed/refractory acute myeloid leukemia (AML).

In cohort 1 of 70 evaluable patients with relapsed/refractory disease, the overall response rate was 33% with the combination and 11% of patients experienced stable disease for more than 6 months; this translated to a clinical benefit rate of approximately 40% to 45%, which exceeds that of standard therapies in AML, says Daver.

According to a propensity-matched analysis between the combination and azacitidine alone, the response rates were approximately doubled with the combination compared with azacitidine alone. Additionally, patients in first relapse were found to derive the greatest benefit from the combination versus those who have relapsed multiple times; this was attributed to a greater depletion of T cells in patients who received several prior lines of therapy.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD